Results 101 to 110 of about 37,220 (200)

The paradox of cancer genes in non-malignant conditions: implications for precision medicine. [PDF]

, 2020
Next-generation sequencing has enabled patient selection for targeted drugs, some of which have shown remarkable efficacy in cancers that have the cognate molecular signatures.
Adashek, Jacob J, Kato, Shumei, Kurzrock, Razelle, Lippman, Scott M   +3 more
core  

Intra-tumor L-methionine level highly correlates with tumor size in both pancreatic cancer and melanoma patient-derived orthotopic xenograft (PDOX) nude-mouse models. [PDF]

, 2018
An excessive requirement for methionine (MET) for growth, termed MET dependence, appears to be a general metabolic defect in cancer. We have previously shown that cancer-cell growth can be selectively arrested by MET restriction such as with recombinant ...
Chemielwski, Bartosz, Dry, Sarah M, Eckardt, Mark A, Eilber, Fritz C, Han, Qinghong, Hoffman, Robert M, Igarashi, Kentaro, Kawaguchi, Kei, Kiyuna, Tasuku, Li, Shukuan, Li, Yunfeng, Miyake, Kentaro, Miyake, Masuyo, Nelson, Scott D, Russell, Tara A, Singh, Arun S, Tan, Yuying, Unno, Michiaki   +17 more
core   +1 more source

Patients With BRAF-Mutant NSCLC May Not Benefit From Immune Checkpoint Inhibitors: A Population-Based Study

JTO Clinical and Research Reports, 2020
Introduction: There is no consensus on whether immune checkpoint inhibitors (ICIs) would offer comparable benefit in mutant-BRAF NSCLC. We, therefore, conducted a study to ascertain the role of ICIs in mutant-BRAF NSCLC. Methods: Records of 4178 patients
Chenxing Zhang, PhD, Chenyue Zhang, PhD, Jiamao Lin, PhD, Zhenxiang Li, PhD, Haiyong Wang, MD   +4 more
doaj   +1 more source

Somatic mutations in solid tumors: a spectrum at the service of diagnostic armamentarium or an indecipherable puzzle? The morphological eyes looking for BRAF and somatic molecular detections on cyto-histological samples [PDF]

, 2016
This review article deals with the analysis and the detection of the morphological features associated with somatic mutations, mostly BRAF(V600E) mutation, on both cytological and histological samples of carcinomas.
Abildgaard, Al-Maghrabi, Amoura, Auclair, Baker, Baltazar, Baltazar, Baltazar, Baltazar, Baltazar, Baltazar, Basolo, Basolo, Bedossa, Biegel, Birner, Birner, Catovsky, Cerutti, Chen, Chiarle, Cho, Choi, Christensen, Ciarrocchi, Clegg, Cornillon, Cox, Cramer, Czyz, Dexter, Diebold, Draetta, Fadda, Fadda, Falini, Fend, Fisher, Flaherty, Frankel, Ghossein, Gilliland, Godeau, Hahn, Hoffmann, Hwang, Iseki, James, Jo, Johnston, Kebebew, Kitamura, Kumar, Kurman, Kurman, Lam, Lee, Leite, Marais, Marais, Marais, Maruyama, McCarthy, Mechtersheimer, Miccoli, Mino-Kenudson, Miziorko, Naidu, Nikiforov, Nikiforov, Nikiforov, Nikiforov, Nikiforova, Odze, Pai, Park do, Pelizzo, Picarsic, Pignata, Prasad, Pujade-Lauraine, Raab, Rollins, Rossi, Saki, Santagata, Santoro, Schmitt, Schmitt, Schmitt, Sciot, Sepulveda, Sharrock, Shih, Shoenfeld, Shong, Sobrinho-Simões, Stokloza, Suh, Tagawa, Tóth, Vandenberghe, Vandenberghe, Vitale, Ward, Waxman, Weitzman, Westerman, White, White, Widlund, Xing, Zenz   +112 more
core   +1 more source

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. [PDF]

, 2012
Drug resistance presents a challenge to the treatment of cancer patients. Many studies have focused on cell-autonomous mechanisms of drug resistance. By contrast, we proposed that the tumour micro-environment confers innate resistance to therapy. Here we
Barzily-Rokni, Michal, Chapman, Paul B, Cooper, Zachary A, Davis, Ashli, Du, Jinyan, Flaherty, Keith T, Frederick, Dennie T, Golub, Todd R, Gould, Joshua, Lo, Roger S, Mongare, Margaret M, Morikawa, Teppei, Ogino, Shuji, Qian, Zhi Rong, Ribas, Antoni, Shee, Kevin, Solit, David B, Straussman, Ravid, Wargo, Jennifer A   +18 more
core   +1 more source

Differential chemosensitivity to antifolate drugs between RAS and BRAF melanoma cells. [PDF]

, 2014
BACKGROUND: The importance of the genetic background of cancer cells for the individual susceptibility to cancer treatments is increasingly apparent.
Arozarena, Imanol, Erice, O., Ferguson, J., Goicoechea, I., Margison, G.P., Wellbrock, C.   +5 more
core   +2 more sources

Immunohistochemical Analysis of BRAF (V600E) Mutation and P16 Expression in Malignant Melanoma in Lagos, Nigeria: A 10-Year Retrospective Study

Journal of Skin Cancer, 2019
Background. In Blacks, malignant melanoma (MM) is associated with greater morbidity and mortality compared to Caucasians. MMs with BRAF V600E mutation as well as those with loss of p16 protein expression are associated with aggressive behavior and worse ...
O. Obadofin, K. Badmos, N. Orsi, M. Bipin, O. Rotimi, A. Banjo   +5 more
doaj   +1 more source

Sete anos de seguimento de uma paciente jovem com carcinoma papílfero de tireóide e mutação de BRAF e perda de expressão de genes do metabolismo de iodo [PDF]

, 2008
BACKGROUND: Recent studies reported that BRAF V600E mutation, the most prevalent genetic event found in papillary thyroid carcinoma, is an independent poor prognostic marker.
Biscolla, Rosa Paula M., Cerutti, Janete Maria, Nakabashi, Claudia D., Oler, Gisele   +3 more
core   +2 more sources

BRAF overexpression is associated with BRAF V600E mutation in papillary thyroid carcinomas

Genetics and Molecular Research, 2015
A common mutation in the BRAF gene, comprising the T1799A nucleotide transversion, which leads to the V600E amino acid substitution in the BRAF protein, has been observed in about 50% of papillary thyroid carcinomas (PTCs). However, BRAF protein expression has been rarely examined in such tumors.
R C, da Silva, H S C, de Paula, C B Q S, Leal, B C R, Cunha, E C, de Paula, R C G, Alencar, A J, Meneghini, A M T C, Silva, A P, Gontijo, I J, Wastowski, V A, Saddi   +10 more
openaire   +2 more sources

Incidence of V600E mutation in patients with papillary thyroid carcinoma: a single-institution experience

Journal of International Medical Research, 2019
Objective Papillary thyroid carcinoma (PTC) accounts for 95% of all thyroid carcinomas. PTC is an epithelial tumor characterized by the proliferation of follicular cells with distinctive nuclear features, and is heterogeneous in terms of its ...
Shoko Kure, Kousuke Ishino, Mitsuhiro Kudo, Ryuichi Wada, Marie Saito, Ryuta Nagaoka, Iwao Sugitani, Zenya Naito   +7 more
doaj   +1 more source